Advances in electrochemical biosensors for early detection of rheumatoid arthritis

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-08-09 DOI:10.1016/j.cca.2025.120547

Elmurod Egamberdiev , Nurali Shavazi , Mustafa Jawad Kadham , Shaxnoza Kasimova , Nilufar Mamatmusayeva , Dildorakhon Nabieva , Guloyim Avezova , Madina Bekchanova , Sanat Chuponov , Nigina Rustamova , Feruza Oripova , Nigora Dustova , Gulchehra Ikhtiyarova

{"title":"Advances in electrochemical biosensors for early detection of rheumatoid arthritis","authors":"Elmurod Egamberdiev , Nurali Shavazi , Mustafa Jawad Kadham , Shaxnoza Kasimova , Nilufar Mamatmusayeva , Dildorakhon Nabieva , Guloyim Avezova , Madina Bekchanova , Sanat Chuponov , Nigina Rustamova , Feruza Oripova , Nigora Dustova , Gulchehra Ikhtiyarova","doi":"10.1016/j.cca.2025.120547","DOIUrl":null,"url":null,"abstract":"<div><div>Electrochemical biosensors have emerged as pivotal technologies for the early detection of rheumatoid arthritis (RA), a chronic autoimmune disease characterized by joint inflammation and destruction. This paper reviews the advancements in biosensing platforms, particularly focusing on the detection of anti-citrullinated peptide antibodies (ACPAs) and other biomarkers relevant to RA diagnosis. By integrating nanotechnology and innovative electrochemical methods, these biosensors offer increased sensitivity, specificity, and rapid results, facilitating timely therapeutic interventions. The review also highlights the challenges and future directions in biosensor technology, emphasizing the importance of personalized medicine and real-time monitoring in improving patient outcomes.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120547"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125004267","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Electrochemical biosensors have emerged as pivotal technologies for the early detection of rheumatoid arthritis (RA), a chronic autoimmune disease characterized by joint inflammation and destruction. This paper reviews the advancements in biosensing platforms, particularly focusing on the detection of anti-citrullinated peptide antibodies (ACPAs) and other biomarkers relevant to RA diagnosis. By integrating nanotechnology and innovative electrochemical methods, these biosensors offer increased sensitivity, specificity, and rapid results, facilitating timely therapeutic interventions. The review also highlights the challenges and future directions in biosensor technology, emphasizing the importance of personalized medicine and real-time monitoring in improving patient outcomes.

查看原文本刊更多论文

电化学生物传感器在类风湿关节炎早期检测中的研究进展。

电化学生物传感器已成为早期检测类风湿性关节炎（RA）的关键技术，类风湿性关节炎是一种以关节炎症和破坏为特征的慢性自身免疫性疾病。本文综述了生物传感平台的进展，重点介绍了抗瓜氨酸肽抗体（ACPAs）和其他与RA诊断相关的生物标志物的检测。通过整合纳米技术和创新的电化学方法，这些生物传感器提供了更高的灵敏度、特异性和快速的结果，促进了及时的治疗干预。该综述还强调了生物传感器技术的挑战和未来方向，强调了个性化医疗和实时监测在改善患者预后方面的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.